Scarica l'app Stockscreener
163.63
0.18%
0.29
Dopo l'orario di chiusura:
163.63
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RGEN Giù?
Forum
Previsione
Precedente Chiudi:
$163.34
Aprire:
$162.26
Volume 24 ore:
455.13K
Relative Volume:
0.61
Capitalizzazione di mercato:
$9.21B
Reddito:
$633.51M
Utile/perdita netta:
$-8.10M
Rapporto P/E:
-527.84
EPS:
-0.31
Flusso di cassa netto:
$131.26M
1 W Prestazione:
+0.18%
1M Prestazione:
-1.55%
6M Prestazione:
+34.41%
1 anno Prestazione:
-2.61%
Intervallo 1D:
$160.26
$164.94
Intervallo di 1 settimana:
$160.22
$174.87
Portata 52W:
$102.97
$182.52
Repligen Corp Stock (RGEN) Company Profile
Nome
Repligen Corp
Settore
Industria
Telefono
(781) 449-9560
Indirizzo
41 SEYON STREET, WALTHAM, MA
Confronta RGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
163.63 | 9.19B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
525.04 | 187.46B | 10.06B | 2.88B | 2.27B | 7.8807 |
|
BDX
Becton Dickinson Co
|
203.40 | 57.96B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.87 | 39.68B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
46.31 | 37.32B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
255.50 | 37.29B | 5.26B | 1.44B | 1.76B | 9.7713 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-01 | Iniziato | HSBC Securities | Buy |
| 2025-09-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-22 | Ripresa | Stephens | Overweight |
| 2025-06-24 | Iniziato | Barclays | Overweight |
| 2025-04-29 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Iniziato | Evercore ISI | In-line |
| 2025-02-10 | Iniziato | TD Cowen | Buy |
| 2024-12-17 | Iniziato | Canaccord Genuity | Hold |
| 2024-11-14 | Iniziato | Wolfe Research | Peer Perform |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-26 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-06-18 | Iniziato | Guggenheim | Neutral |
| 2023-12-04 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-07-20 | Iniziato | Wells Fargo | Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-03-28 | Iniziato | The Benchmark Company | Buy |
| 2022-12-14 | Iniziato | Deutsche Bank | Hold |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | Iniziato | UBS | Buy |
| 2021-10-14 | Iniziato | Exane BNP Paribas | Outperform |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-11-01 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | Iniziato | SVB Leerink | Outperform |
| 2019-08-28 | Reiterato | First Analysis Sec | Outperform |
| 2019-08-23 | Ripresa | Stephens | Overweight |
| 2019-07-22 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | Aggiornamento | CL King | Neutral → Buy |
| 2018-11-12 | Downgrade | CL King | Buy → Neutral |
| 2018-09-26 | Iniziato | H.C. Wainwright | Neutral |
| 2017-12-08 | Iniziato | Citigroup | Buy |
| 2017-12-05 | Iniziato | JP Morgan | Overweight |
| 2017-11-13 | Iniziato | CL King | Buy |
| 2017-10-02 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | Iniziato | William Blair | Outperform |
| 2017-02-13 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
Mostra tutto
Repligen Corp Borsa (RGEN) Ultime notizie
Pharma News: Can Repligen Corporation navigate macro headwindsMarket Sentiment Review & Safe Entry Point Identification - mfd.ru
UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds - Insider Monkey
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Repligen Corp (RGEN) Shares Up 3.89% on Jan 21 - GuruFocus
Single-Use Bioprocessing Market Projected to Reach US$ 122.92 Billion by 2035, Supported by Expansion of Biomanufacturing Capacity Says Astute Analytica - GlobeNewswire Inc.
Slow Capital Inc. Has $5.89 Million Holdings in Repligen Corporation $RGEN - MarketBeat
Is It Too Late To Consider Buying Repligen Corporation (NASDAQ:RGEN)? - Yahoo Finance
Stephens Investment Management Group LLC Grows Stock Position in Repligen Corporation $RGEN - MarketBeat
Expert Outlook: Repligen Through The Eyes Of 5 Analysts - Benzinga
UBS raises Repligen stock price target to $200 on bioprocessing recovery - Investing.com
Why Repligen (RGEN) Shares Are Sliding Today - Finviz
Repligen Corp. Seeks M&A Opportunities - marketscreener.com
Published on: 2026-01-13 17:35:09 - Bộ Nội Vụ
Conestoga Capital Advisors LLC Has $127.91 Million Position in Repligen Corporation $RGEN - Defense World
Is Repligen Corporation stock gaining market share2025 Volatility Report & Growth Oriented Trading Recommendations - ulpravda.ru
Can Repligen Corporation stock hit record highs againJuly 2025 Levels & AI Powered Market Trend Analysis - Улправда
Repligen appoints Madaus as new board chair, Hunt to retire By Investing.com - Investing.com Canada
Repligen appoints Madaus as new board chair, Hunt to retire - Investing.com
Repligen Corporation Elects Dr. Martin D. Madaus as New Chair of the Board, Succeeding Tony Hunt - Quiver Quantitative
Repligen Corp Announces New Chair of the Board - TradingView — Track All Markets
Longtime Repligen leader steps down as new board chair takes over in 2026 - Stock Titan
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair - marketscreener.com
Repligen Corporation (RGEN): Investor Outlook with a 15% Upside Potential in the Bioprocessing Sector - DirectorsTalk Interviews
Institution Moves: How risky is Repligen Corporation RGN stock compared to peersMarket Risk Report & Risk Controlled Stock Pick Alerts - Bộ Nội Vụ
About Us - FinancialContent
Pacer Advisors Inc. Has $1.37 Million Position in Repligen Corporation $RGEN - MarketBeat
Allspring Global Investments Holdings LLC Lowers Stake in Repligen Corporation $RGEN - MarketBeat
Delta Investment Management LLC Buys Shares of 50,717 Repligen Corporation $RGEN - MarketBeat
Repligen Corporation (NASDAQ:RGEN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Why Repligen Corporation stock remains undervaluedFibonacci Retracement Levels & Free Dynamic Capital Growth - bollywoodhelpline.com
Is Repligen (RGEN) Quietly Recasting Its Gene Therapy Moat With New HiPer Viral Vector Resins? - simplywall.st
Riverbridge Partners LLC Sells 24,644 Shares of Repligen Corporation $RGEN - MarketBeat
Congress Asset Management Co. Boosts Stake in Repligen Corporation $RGEN - Defense World
Assenagon Asset Management S.A. Takes Position in Repligen Corporation $RGEN - MarketBeat
Can Repligen Corporation stock maintain growth trajectoryFed Meeting & Smart Allocation Stock Tips - Улправда
Texas Permanent School Fund Corp Has $3.13 Million Stock Holdings in Repligen Corporation $RGEN - MarketBeat
Will Repligen Corporation stock rally after Fed decisions2025 Winners & Losers & Free Technical Pattern Based Buy Signals - Улправда
Why Repligen Corporation (RGN) stock trades below fair valueJuly 2025 Drop Watch & Risk Managed Investment Signals - Bölüm Sonu Canavarı
Repligen (RGEN): Assessing Valuation After New Chromatography Resins Expand Its Gene Therapy Toolkit - simplywall.st
How institutional buying supports Repligen Corporation stockJuly 2025 Highlights & High Accuracy Investment Signals - Улправда
Insider Sell: Karen Dawes Sells Shares of Repligen Corp (RGEN) - GuruFocus
Repligen (NASDAQ:RGEN) Director Karen Dawes Sells 275 Shares - MarketBeat
REPLIGEN Director Karen A Dawes Sells 275 Shares - TradingView — Track All Markets
[Form 4] REPLIGEN CORP Insider Trading Activity - Stock Titan
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference - Yahoo Finance
Here’s Why Sands Capital Global Growth Fund Decided to Sell Repligen Corporation (RGEN) - Insider Monkey
The Bull Case For Repligen (RGEN) Could Change Following New Gene Therapy Chromatography Resin Launches - simplywall.st
Repligen (RGEN) Expands Product Line with High-Performance Chrom - GuruFocus
Repligen Corporation Launches Three New High-Performance Chromatography Resins to Enhance Bioprocessing Solutions - Quiver Quantitative
Repligen Corp Azioni (RGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
0.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):